Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2018 Mar 16

PMID 29543755

Citations 80

Authors

Fabio Sonvico

Adryana Clementino

Francesca Buttini

Gaia Colombo

Silvia Pescina

Silvia Staniscuaski Guterres

Adriana Raffin Pohlmann

Sara Nicoli

Affiliations

Soon will be listed here.

Abstract

In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer's disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose's upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.

Citing Articles

Evaluation the toxic effects of Cobalt-Zinc Ferrite nanoparticles in experimental mice.

El-Nahass E, Salem B, El-Naggar S, Elwan M Sci Rep. 2025; 15(1):6903.

PMID: 40011491 PMC: 11865507. DOI: 10.1038/s41598-025-90043-x.

Lipid-core nanocapsules containing simvastatin do not affect the biochemical and hematological indicators of toxicity in rats.

Lorenzoni R, Davies S, Cordenonsi L, Roggia I, Vicosa J, Mezzomo N Toxicol Res (Camb). 2024; 13(6):tfae189.

PMID: 39539252 PMC: 11557222. DOI: 10.1093/toxres/tfae189.

In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer's Disease Therapy.

Lee D, Shen A, Shah M, Garbuzenko O, Minko T Int J Mol Sci. 2024; 25(19).

PMID: 39408684 PMC: 11476875. DOI: 10.3390/ijms251910357.

Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma.

Devi C, Deka K, Das A, Talukdar A, Sola P Mol Biotechnol. 2024; .

PMID: 39327380 DOI: 10.1007/s12033-024-01287-3.

Brain-targeted intranasal delivery of protein-based gene therapy for treatment of ischemic stroke.

Ryu J, Cerecedo-Lopez C, Yang H, Ryu I, Du R Theranostics. 2024; 14(12):4773-4786.

PMID: 39239521 PMC: 11373627. DOI: 10.7150/thno.98088.

References

Comfort C, Garrastazu G, Pozzoli M, Sonvico F . Opportunities and challenges for the nasal administration of nanoemulsions. Curr Top Med Chem. 2015; 15(4):356-68. DOI: 10.2174/1568026615666150108144655. View

Piazza J, Hoare T, Molinaro L, Terpstra K, Bhandari J, Selvaganapathy P . Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia. Eur J Pharm Biopharm. 2014; 87(1):30-9. DOI: 10.1016/j.ejpb.2014.02.007. View

Duchi S, Ovadia H, Touitou E . Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol. 2013; 258(1-2):32-40. DOI: 10.1016/j.jneuroim.2013.02.013. View

Lungare S, Hallam K, Badhan R . Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery. Int J Pharm. 2016; 513(1-2):280-293. DOI: 10.1016/j.ijpharm.2016.09.042. View

Pardeshi C, Belgamwar V . Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013; 10(7):957-72. DOI: 10.1517/17425247.2013.790887. View

Liu Q, Shen Y, Chen J, Gao X, Feng C, Wang L . Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm Res. 2011; 29(2):546-58. DOI: 10.1007/s11095-011-0641-0. View

Mistry A, Stolnik S, Illum L . Nose-to-Brain Delivery: Investigation of the Transport of Nanoparticles with Different Surface Characteristics and Sizes in Excised Porcine Olfactory Epithelium. Mol Pharm. 2015; 12(8):2755-66. DOI: 10.1021/acs.molpharmaceut.5b00088. View

Sekerdag E, Lule S, Bozdag Pehlivan S, Ozturk N, Kara A, Kaffashi A . A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles. J Control Release. 2017; 261:187-198. DOI: 10.1016/j.jconrel.2017.06.032. View

Merkus F, van den Berg M . Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Drugs R D. 2007; 8(3):133-44. DOI: 10.2165/00126839-200708030-00001. View

10.

Xu Q, Ensign L, Boylan N, Schon A, Gong X, Yang J . Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. ACS Nano. 2015; 9(9):9217-27. PMC: 4890729. DOI: 10.1021/acsnano.5b03876. View

11.

Mistry A, Stolnik S, Illum L . Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009; 379(1):146-57. DOI: 10.1016/j.ijpharm.2009.06.019. View

12.

Kirch J, Schneider A, Abou B, Hopf A, Schaefer U, Schneider M . Optical tweezers reveal relationship between microstructure and nanoparticle penetration of pulmonary mucus. Proc Natl Acad Sci U S A. 2012; 109(45):18355-60. PMC: 3494950. DOI: 10.1073/pnas.1214066109. View

13.

Lemarchand C, Gref R, Couvreur P . Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004; 58(2):327-41. DOI: 10.1016/j.ejpb.2004.02.016. View

14.

Peterson A, Bansal A, Hofman F, Chen T, Zada G . A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option. J Neurooncol. 2014; 116(3):437-46. DOI: 10.1007/s11060-013-1346-5. View

15.

Yang M, Lai S, Yu T, Wang Y, Happe C, Zhong W . Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J Control Release. 2014; 192:202-8. PMC: 4194208. DOI: 10.1016/j.jconrel.2014.07.045. View

16.

Bhatt R, Singh D, Prakash A, Mishra N . Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. Drug Deliv. 2014; 22(7):931-9. DOI: 10.3109/10717544.2014.880860. View

17.

Raj R, Wairkar S, Sridhar V, Gaud R . Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2017; 109:27-35. DOI: 10.1016/j.ijbiomac.2017.12.056. View

18.

Abdelrahman F, Elsayed I, Gad M, Hassen Elshafeey A, Mohamed M . Response surface optimization, Ex vivo and In vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. Int J Pharm. 2017; 530(1-2):1-11. DOI: 10.1016/j.ijpharm.2017.07.050. View

19.

Merkus , Verhoef , Schipper , Marttin . Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 2000; 29(1-2):13-38. DOI: 10.1016/s0169-409x(97)00059-8. View

20.

Schuster B, Suk J, Woodworth G, Hanes J . Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials. 2013; 34(13):3439-46. PMC: 3590854. DOI: 10.1016/j.biomaterials.2013.01.064. View